PA
EFTR

Parallel Advisors’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Parallel Advisors’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-67,738
Closed -$19.7K – 3511
2024
Q2 		$19.7K Hold
67,738
– – ﹤0.01% 1994
2024
Q1 		$975K Sell
67,738
-4
-0% -$48 0.03% 369
2023
Q4 		$792K Hold
67,742
– – 0.02% 383
2023
Q3 		$1.02M Hold
67,742
– – 0.03% 309
2023
Q2 		$1.41M Hold
67,742
– – 0.05% 258
2023
Q1 		$597K Hold
67,742
– – 0.02% 410
2022
Q4 		$724K Hold
67,742
– – 0.03% 322
2022
Q3 		$969K Hold
67,742
– – 0.04% 244
2022
Q2 		$2.4M Buy
67,742
+40,644
+150% +$2.46M 0.11% 128
2022
Q1 		$2.74M Buy
+27,098
New +$3.6M 0.11% 130
2021
Q3 		– Sell
-10
Closed -$2K – 3316
2021
Q2 		$2K Buy
+10
New +$2.46K ﹤0.01% 2642

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Parallel Advisors's EFTR Position: Q3 2024 in Review

Parallel Advisors sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 67,738 shares — an estimated $19.7K sold.

Parallel Advisors first reported a position in EFTR in Q2 2021 and held it in 11 quarters. The position peaked at $2.74M in Q1 2022. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

  • Parallel Advisors reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Parallel Advisors sold 67,738 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $19.7K.
  • Parallel Advisors first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
  • Parallel Advisors's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $2.74M in Q1 2022.
  • 3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.